A Neuralink Co-Founder's Startup Could Beat Everyone to Market

The brain-computer interface industry just passed a critical inflection point. On March 5, 2026, Science Corporation announced the close of a $230 million Series C round, valuing the company at $1.5 billion — officially minting a new unicorn in the neurotechnology space. The round was backed by Lightspeed Venture Partners, Khosla Ventures, Y Combinator, IQT (In-Q-Tel), and Quiet Capital, bringing the company's total funding to approximately $490 million since its founding in 2021.

What makes this raise particularly significant isn't just the dollar amount. Science Corp is positioning itself to become the first BCI company to bring a commercial product to market, with a CE mark application already submitted to the European Union and approval expected by mid-2026. While Elon Musk's Neuralink commands a $9 billion valuation and dominates headlines, Science Corp may quietly win the race that matters most: getting a working device into patients' hands.

From Neuralink's C-Suite to a $1.5B Competitor

Science Corp was founded in April 2021 by Max Hodak and Alan Mardinly, both former members of Neuralink's leadership team. Hodak's pedigree in the field runs deep — he started programming at age six, worked in pioneering neuroscientist Miguel Nicolelis's lab at Duke University as an undergraduate, and in 2016 co-founded Neuralink alongside Elon Musk. As Neuralink's president, Hodak ran day-to-day operations from the company's inception through early 2021.

When Hodak departed Neuralink, he took three colleagues with him to start Science Corp. The move raised eyebrows across Silicon Valley — and for good reason. This wasn't a first-time founder taking a speculative bet on an emerging technology. This was the person who operationalized Neuralink's vision deciding he could build something better.

Today, Science Corp employs approximately 282 people across three locations: its headquarters in Alameda, California; a manufacturing facility in Research Triangle Park, North Carolina; and an office in Paris, France. The North Carolina facility is particularly strategic — the company acquired MEMS (microelectromechanical systems) manufacturing assets there, enabling in-house chip production that reduces both iteration timelines and costs.

PRIMA: A Grain-of-Rice-Sized Implant That Restores Sight

Science Corp's flagship product is PRIMA, a subretinal photovoltaic implant designed to restore functional vision in patients with advanced age-related macular degeneration (AMD). The device is smaller than a grain of rice and comprises 378 independently controlled pixels, each equipped with a tiny electrode.

The technology works through an elegantly simple mechanism. A pair of specialized glasses equipped with a camera and infrared projector captures visual information, converts it to infrared light patterns, and beams them to the implant. Each pixel converts the infrared signal into electrical stimulation of the retina's bipolar cells — effectively bypassing the photoreceptor cells (rods and cones) that have been destroyed by disease and restoring visual input to the brain.

Science Corp acquired the PRIMA technology in 2024 through its purchase of French company Pixium Vision's assets, then significantly accelerated development. The approach represents a fundamentally different bet than Neuralink's: rather than drilling into the skull for direct brain access, PRIMA targets the eye through a far less invasive procedure, dramatically improving patient accessibility and reducing surgical risk.

Peer-Reviewed Results: The Data That Convinced Investors

The clinical evidence behind PRIMA is the strongest card in Science Corp's hand. In October 2025, results from the PRIMAvera pivotal trial were published in the New England Journal of Medicine — the gold standard of medical research.

The numbers are compelling:

• 38 patients across 17 clinical sites in 5 countries with geographic atrophy from age-related macular degeneration
• Mean improvement of 25.5 letters on the ETDRS chart (more than 5 lines of visual acuity)
• 80% of patients achieved clinically meaningful improvement of at least logMAR 0.2 (p<0.001)
• 84% reported the ability to read letters, numbers, and words
• Strong safety profile: 95% of serious adverse events resolved within 2 months; no significant peripheral vision decline observed

The study was led by Dr. Frank Holz, Chair of Ophthalmology at the University Hospital of Bonn, with Prof. José-Alain Sahel of the University of Pittsburgh and Sorbonne Université as senior co-author. The trial's Data Safety Monitoring Board recommended European market approval based on these results.

For context, an NEJM publication with this kind of efficacy data is extraordinarily rare for a medical device at this stage. It sends an unambiguous signal to regulators, clinicians, and investors alike.

The Investors and What They're Buying Into

The Series C syndicate tells a story about the breadth of conviction around Science Corp:

• Lightspeed Venture Partners — one of Silicon Valley's premier venture firms, signaling belief in Science Corp's commercial viability
• Khosla Ventures — a repeat investor that led the company's $104 million convertible note round in April 2025 and doubled down in the Series C
• Y Combinator — the world's most prominent startup accelerator, extending its support beyond the typical early-stage sweet spot
• IQT (In-Q-Tel) — the nonprofit investment arm serving U.S. intelligence agencies, suggesting Science Corp's technology has applications beyond civilian medicine
• Quiet Capital — a tech-focused investment firm

Khosla's repeat participation is particularly telling. In venture capital, when a lead investor from the previous round returns at a higher valuation, it's one of the strongest signals of insider confidence. The presence of IQT adds an intriguing dimension — it implies that government and defense agencies see strategic value in BCI technology for vision restoration and potentially broader neural interface applications.

Competitive Landscape: A Crowded Field With Few Near-Term Winners

The BCI sector now counts approximately 275 companies globally, with 159 funded ventures having raised a collective $3.74 billion. The U.S. dominates with $2.55 billion in total investment. But the competitive dynamics are more nuanced than raw funding totals suggest.

Neuralink remains the sector's 800-pound gorilla, having raised over $1 billion including a $650 million Series E in June 2025 at a $9 billion valuation. Its direct brain-implant approach targets a broader set of applications — from motor function restoration to potential cognitive enhancement — but it remains in early clinical stages with a far longer road to commercial launch.

Synchron, with $145 million in funding, takes a differentiated approach by threading its BCI through blood vessels rather than requiring open brain surgery. It boasts the most patients in clinical trials after Blackrock Neurotech.

Paradromics ($108.6 million raised) completed its first human surgery in June 2025, while Precision Neuroscience ($93 million+) uses a surface-of-brain device that avoids penetrating neural tissue.

Two new entrants are also worth watching: Merge Labs, backed by Sam Altman and OpenAI, and China's Neuracle, which recently won the first-ever commercial approval for an implantable BCI in China.

Science Corp's competitive advantage is its proximity to commercialization. While most competitors are still navigating clinical trials, Science Corp has submitted its CE mark application and expects European approval within months. In medical devices, being first to market creates powerful network effects — surgeon training, patient data accumulation, and reimbursement pathway establishment all compound over time.

Use of Funds: From Lab to Global Scale

Science Corp plans to deploy the $230 million across four strategic priorities:

1. PRIMA Commercialization. The most immediate use of capital is preparing for the European commercial launch, starting with Germany. This means manufacturing scale-up, building a commercial organization (sales, marketing, medical affairs), and establishing reimbursement frameworks. In parallel, the company is pursuing FDA approval in the United States.

2. Indication Expansion. While PRIMA currently targets geographic atrophy from AMD, Science Corp is evaluating the technology for Stargardt disease and retinitis pigmentosa — expanding the total addressable patient population significantly. Age-related macular degeneration alone affects an estimated 200 million people worldwide.

3. Next-Generation Technology. The company is developing biohybrid neural interfaces using engineered neurons derived from stem cells — a potentially transformative approach that could overcome the fundamental limitations of electrode-based BCIs, including signal degradation over time.

4. The Vessel Program. In a less publicized initiative, Science Corp is working on portable organ preservation technology — a signal that the company sees itself as a broader biotech platform rather than a single-product company.

Why This Matters: BCI's Commercial Moment

The brain-computer interface field has long been characterized by extraordinary scientific ambition and glacial commercial progress. Science Corp's trajectory suggests that dynamic is finally changing.

The combination of NEJM-published clinical data, a submitted regulatory application, a clear path to commercial launch, and nearly half a billion in funding creates a profile that is rare in the BCI space — or in medtech more broadly. If Science Corp receives CE mark approval in mid-2026 as expected, it will mark a watershed moment: the first time a brain-computer interface technology has been commercially available for patient treatment.

For investors, the key metrics to watch in the coming quarters are: CE mark approval timing, initial European revenue figures, FDA regulatory progress, and any new clinical data on expanded indications. For the BCI industry as a whole, Science Corp's commercial launch — if it happens — will serve as the ultimate proof of concept that this technology can transition from laboratory marvel to therapeutic reality.

2026 may well be remembered as the year brain-computer interfaces graduated from science fiction to medical practice. And Science Corp, built by the people who helped create Neuralink and then left to do it differently, is leading that charge.